ClinicalTrials.gg
CompletedNCT02333071HSDDUpdated Apr 9, 2021Results posted

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

A Phase 3 interventional study of Bremelanotide and Placebo in Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies, Inc. Completed at 91 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Palatin Technologies, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
723
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Enrollment
11th of 59
723 · median 196
Started
2014
the only one that year
Phase 3
26 of 62
none open now
Registered
41st of 62
by date
Lead sponsor
4 of 62
Palatin Technologies, Inc

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 11th largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2014, is one of 26 in phase 3, and was the 41st registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Read the detailed description

This will be a multicenter, randomized, placebo-controlled, parallel group study in up to 80 sites in the United States of America (USA) and Canada to evaluate the efficacy and safety of a fixed dose of SC BMT versus placebo on an as-needed basis under conditions of home use in premenopausal women with HSDD (with or without decreased arousal).

The study will consist of 2 phases: (1) Core Study: 4-week no-treatment qualification period, a 4-week single-blind placebo treatment period (baseline), and a 24-week double-blind treatment period where participants will self-administer placebo or BMT 1.75 mg SC via an autoinjector; and (2) Extension Phase: a 52-week open-label treatment period during which all subjects will receive BMT 1.75 mg.

Primary Objective

  • To evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Secondary Objectives

  • To evaluate the efficacy of BMT in premenopausal women in the double-blind Core Study, as assessed by subject responses to questionnaires measuring sexual function, treatment satisfaction, and distress associated with sexual dysfunction.
  • To evaluate the safety of BMT in premenopausal women in the double-blind Core Study.
  • To evaluate the safety of long-term therapy with BMT in the open label Extension Phase.
  • To evaluate the efficacy of long-term therapy with BMT in the open-label Extension Phase.
03

Conditions studied

  • Hypoactive Sexual Desire Disorder

Keywords

  • HSDD
  • Female Sexual Desire Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Has met diagnostic criteria for HSDD for at least 6 months
  • Is willing and able to understand and comply with all study requirements
  • Has a normal pelvic examination at screening

Main Exclusion Criteria:

  • Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results
  • Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
723 participants (actual)

Study arms

  • Experimental
    Bremelanotide (BMT/BMT)

    (Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks (OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks

    Drug: Bremelanotide

  • Placebo comparator
    Placebo (PBO/BMT)

    (Main Study) PBO administered SC on an as-desired basis for 24 weeks (OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks

    Drug: Bremelanotide · Other: Placebo

Interventions

  • A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

    Also known as: BMT, PT-141

  • OtherPlacebo

    Placebo

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.

    As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain. FSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  2. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)

    As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (Female Sexual Distress Scale - Desire Arousal Orgasm) (item 13).: co-primary endpoint - FSDS-DAO bothered by low desire item 13. Responses range from 0 (never) to 4 (always). Decreasing scores on this scale represent an increase in sexual desire (positive outcome).

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

Secondary outcomes

  1. Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration

    Patient's change, from baseline to end of study (EOS), in the number of Satisfying Sexual Events (SSEs), as measured by a response of 'Yes' to question 10 (Q10) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). The end point was calculated as the number of events during the last 4 weeks of treatment with Q10 = Yes minus the number of baseline events with Q10 = Yes.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  2. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R

    Scores range from 0 (no desire) to 3 (high desire) for an individual encounter. Change from baseline is computed as the mean of the scores from all encounters for a subject in the last 28 days minus the mean of the scores from all encounters for the subject in the last 28 days before Visit 3. Only FSEP-R data pertaining to encounters recorded within 72 hours of the encounter are included.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  3. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R

    Patient's change, from baseline to end of study (EOS), in mean satisfaction with desire score, as measured by a response to question 4 (Q4) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). Responses range from 1 (Not at all satisfied) to 4 (Completely satisfied).

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  4. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the FSDS-DAO Total Score

    FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm Scores range from 0 (never feel bothered) to 60 (always feel bothered).

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  5. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total FSFI Total Score

    FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  6. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R

    FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  7. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R

    FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  8. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO

    FSDS-DAO = Female Sexual Distress Scale-Desire/Arousal/Orgasm. The outcome reported is the mean score from the 15-item self assessment. The result is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  9. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)

    FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a better outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  10. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total Number of SSEs

    Change from Baseline to EOS in the total number of satisfying sexual events SSEs that occurred within 16 hours of a study drug dosing and reported within 72 hours. A higher value indicates a better outcome.

    Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

  11. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase

    FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

    Time frame: 24 weeks (Main Study)

  12. Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase

    FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome. The score is the mean change from Baseline observed at EOS (Baseline score - EOS score) for FSDS-DAO Item 13 (feeling bothered by low sexual desire).

    Time frame: 24 weeks (Main Study)

  13. Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase

    Mean change from Baseline to EOS in the number of satisfying sexual events SSEs that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number reflects a positive outcome.

    Time frame: 24 weeks (Main Study)

07

Results

Posted Dec 23, 2020

Participant flow

Core ("Main") Study consisted of a 4-week no drug Screening period, followed by a 4-week single blind PBO period, first dose administered in-clinic. Following the end of single-blind period, which served as Baseline, eligible subjects were then randomized to a 24-week double-blind outpatient treatment period, first dose administered in-clinic.

Core Study
Participant flow — Core Study
MilestonePlacebo PBO/BMTBremelanotide BMT/BMT
Started326327
Received intervention319324
Completed274190
Not completed52137
Open Label Extension
Participant flow — Open Label Extension
MilestonePlacebo PBO/BMTBremelanotide BMT/BMT
Started239124
Completed9549
Not completed14475

Outcome measures

PrimaryEfficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.

As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain. FSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.54 ± 1.1060.24 ± 0.994
Open label extension1.30 ± 1.1050.77 ± 1.138
PrimaryEfficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)

As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (Female Sexual Distress Scale - Desire Arousal Orgasm) (item 13).: co-primary endpoint - FSDS-DAO bothered by low desire item 13. Responses range from 0 (never) to 4 (always). Decreasing scores on this scale represent an increase in sexual desire (positive outcome).

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study-0.73 ± 1.203-0.36 ± 1.082
Open label extension-1.7 ± 1.21-0.9 ± 1.10
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration

Patient's change, from baseline to end of study (EOS), in the number of Satisfying Sexual Events (SSEs), as measured by a response of 'Yes' to question 10 (Q10) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). The end point was calculated as the number of events during the last 4 weeks of treatment with Q10 = Yes minus the number of baseline events with Q10 = Yes.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · events
Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration
eventsBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.0 ± 1.44-0.1 ± 1.35
Open label extension0.28 ± 1.4570.10 ± 1.189
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R

Scores range from 0 (no desire) to 3 (high desire) for an individual encounter. Change from baseline is computed as the mean of the scores from all encounters for a subject in the last 28 days minus the mean of the scores from all encounters for the subject in the last 28 days before Visit 3. Only FSEP-R data pertaining to encounters recorded within 72 hours of the encounter are included.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.0 ± 1.090.1 ± 0.92
Open label extension0.66 ± 0.9750.38 ± 1.107
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R

Patient's change, from baseline to end of study (EOS), in mean satisfaction with desire score, as measured by a response to question 4 (Q4) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). Responses range from 1 (Not at all satisfied) to 4 (Completely satisfied).

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.2 ± 1.150.0 ± 0.96
Open label extension0.93 ± 1.1410.59 ± 1.054
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the FSDS-DAO Total Score

FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm Scores range from 0 (never feel bothered) to 60 (always feel bothered).

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the FSDS-DAO Total Score
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study-9.2 ± 13.86-5.5 ± 12.27
Open label extension-21.4 ± 13.96-12.0 ± 13.66
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total FSFI Total Score

FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total FSFI Total Score
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study2.69 ± 7.3170.95 ± 5.963
Open label extension7.71 ± 8.0763.95 ± 6.740
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R

FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.1 ± 1.11-0.1 ± 0.93
Open label extension0.65 ± 1.0350.43 ± 1.029
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R

FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.2 ± 1.20-0.1 ± 1.02
Open label extension0.99 ± 1.1700.60 ± 1.116
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO

FSDS-DAO = Female Sexual Distress Scale-Desire/Arousal/Orgasm. The outcome reported is the mean score from the 15-item self assessment. The result is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study-0.6 ± 1.24-0.4 ± 1.07
Open label extension-1.5 ± 1.23-1.0 ± 1.12
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)

FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a better outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)
score on a scaleBremelanotide BMT/BMTPlacebo PBO/BMT
Main study0.66 ± 1.5960.16 ± 1.240
Open label extension1.46 ± 1.7241.08 ± 1.581
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total Number of SSEs

Change from Baseline to EOS in the total number of satisfying sexual events SSEs that occurred within 16 hours of a study drug dosing and reported within 72 hours. A higher value indicates a better outcome.

Time frame:
8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Reported as:
Mean · events
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total Number of SSEs
eventsBremelanotide BMT/BMTPlacebo PBO/BMT
Main study-0.1 ± 1.76-0.2 ± 1.79
Open label extension0.65 ± 1.6760.05 ± 1.553
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase

FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

Time frame:
24 weeks (Main Study)
Reported as:
Mean · score on a scale
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase
score on a scaleBremelanotide BMTPlacebo PBO
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase0.69 ± 1.1140.23 ± 0.933
SecondaryChange From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase

FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome. The score is the mean change from Baseline observed at EOS (Baseline score - EOS score) for FSDS-DAO Item 13 (feeling bothered by low sexual desire).

Time frame:
24 weeks (Main Study)
Reported as:
Mean · score on a scale
Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase
score on a scaleBremelanotide BMTPlacebo PBO
Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase-0.9 ± 1.23-0.3 ± 1.05
SecondaryEfficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase

Mean change from Baseline to EOS in the number of satisfying sexual events SSEs that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number reflects a positive outcome.

Time frame:
24 weeks (Main Study)
Reported as:
Mean · events
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase
eventsBremelanotide BMTPlacebo PBO
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase0.1 ± 1.66-0.1 ± 1.37

Adverse events

Collected over 6 months (Main study), 12 months (Open Label study). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bremelanotide (Main Study)0/324 (0%)4/324 (1.2%)255/324 (78.7%)
Placebo (Main Study)0/319 (0%)1/319 (0.3%)160/319 (50.2%)
Bremelanotide (OLE)0/124 (0%)0/124 (0%)95/124 (76.6%)
Placebo (OLE)0/239 (0%)2/239 (0.8%)200/239 (83.7%)
Most frequent serious events
Most frequent serious events
EventBremelanotide (Main Study)Placebo (Main Study)Bremelanotide (OLE)Placebo (OLE)
Cerebrovascular accidentCardiac disorders0/3240/3190/1241/239
EndometriosisPregnancy, puerperium and perinatal conditions0/3240/3190/1241/239
ColitisGastrointestinal disorders0/3241/3190/1240/239
Abdominal hernia obstructiveGastrointestinal disorders1/3240/3190/1240/239
Peritoneal hemorrhageGastrointestinal disorders1/3240/3190/1240/239
VomitingGastrointestinal disorders1/3240/3190/1240/239
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3240/3190/1240/239
HeadacheNervous system disorders1/3240/3190/1240/239
Ovarian cyst rupturedReproductive system and breast disorders1/3240/3190/1240/239
Most frequent other events
Showing 10 of 25
Most frequent other events
EventBremelanotide (Main Study)Placebo (Main Study)Bremelanotide (OLE)Placebo (OLE)
NauseaGastrointestinal disorders138/3247/31946/124109/239
FlushingVascular disorders84/3242/31924/12465/239
SunburnInjury, poisoning and procedural complications10/32433/31912/12433/239
HeadacheNervous system disorders32/3248/31913/12431/239
Upper respiratory tract infectionInfections and infestations22/32425/31911/12417/239
Injection site painGeneral disorders15/32420/3193/12420/239
Urinary tract infectionInfections and infestations13/32421/3199/1246/239
FatigueGeneral disorders12/3241/3194/12417/239
VomitingGastrointestinal disorders17/3240/3193/12415/239
Injection site reactionGeneral disorders18/3243/3192/12414/239

Baseline characteristics

A total of 653 subjects were randomized into the double-blind period of the study; 10 subjects were not dosed, therefore total = 643. A total of 363 of the 464 (78.2%) subjects who completed the Core Study Phase continued into the optional OLE Study Phase.

Age, Continuous
Age, Continuous(Years)Bremelanotide (BMT/BMT)Placebo (PBO/BMT)Total
Main38.4 ± 6.9538.5 ± 7.2238.5 ± 7.08
OLE38.5 ± 6.7238.8 ± 6.9338.7 ± 6.85
Sex: Female, Male
Sex: Female, Male(Participants)Bremelanotide (BMT/BMT)Placebo (PBO/BMT)Total
Main — Female324319643
Main — Male000
OLE — Female124239363
OLE — Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bremelanotide (BMT/BMT)Placebo (PBO/BMT)Total
Main — Hispanic or Latino333164
Main — Not Hispanic or Latino291288579
Main — Unknown or Not Reported000
OLE — Hispanic or Latino132033
OLE — Not Hispanic or Latino111219330
OLE — Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bremelanotide (BMT/BMT)Placebo (PBO/BMT)Total
Main — American Indian or Alaska Native314
Main — Asian235
Main — Native Hawaiian or Other Pacific Islander000
Main — Black or African American444286
Main — White273269542
Main — More than one race134
Main — Unknown or Not Reported112
OLE — American Indian or Alaska Native202
OLE — Asian224
OLE — Native Hawaiian or Other Pacific Islander000
OLE — Black or African American172946
OLE — White101204305
OLE — More than one race134
OLE — Unknown or Not Reported112
08

Study locations

91 sites
  • Palatin Clinical Site 121
    Birmingham, Alabama 35211, United States
  • Palatin Clinical Site 110
    Huntsville, Alabama 35801, United States
  • Palatin Clinical Site 106
    Mobile, Alabama 36608, United States
  • Palatin Clinical Site 149
    Scottsdale, Arizona 85251, United States
  • Palatin Clinical Site 157
    Tucson, Arizona 85712, United States
  • Palatin Clinical Site 166
    Little Rock, Arkansas 72205, United States
  • Palatin Clinical Site 102
    National City, California 91950, United States
  • Palatin Clinical Site 164
    Oceanside, California 92056, United States
  • Palatin Clinical Site 152
    Orange, California 92868, United States
  • Palatin Clinical Site 188
    Sacramento, California 95821, United States
  • Palatin Clinical Site 141
    San Diego, California 92103, United States
  • Palatin Clinical Site 187
    Walnut Creek, California 94598, United States
  • Palatin Clinical Site 160
    Centennial, Colorado 80239, United States
  • Palatin Clinical Site 185
    Colorado Springs, Colorado 80907, United States
  • Palatin Clinical Site 130
    Bradenton, Florida 34208, United States
  • Palatin Clinical Site 128
    Hollywood, Florida 33024, United States
  • Palatin Clinical Site 134
    Jacksonville, Florida 32256, United States
  • Palatin Clinical Site 108
    Melbourne, Florida 32934, United States
  • Palatin Clinical Site 105
    Orlando, Florida 32801, United States
  • Palatin Clinical Site 144
    Saint Petersburg, Florida 33709, United States
  • Palatin Clinical Site 131
    South Miami, Florida 33143, United States
  • Palatin Clinical Site 101
    West Palm Beach, Florida 33401, United States
  • Palatin Clinical Site 116
    Decatur, Georgia 30030, United States
  • Palatin Clinical Site 142
    Savannah, Georgia 31406, United States
  • Palatin Clinical Site 171
    Meridian, Idaho 83642, United States
  • Palatin Clinical Site 179
    Evansville, Indiana 47710, United States
  • Palatin Clinical Site 165
    Lafayette, Indiana 47905, United States
  • Palatin Clinical Site 154
    Mishawaka, Indiana 46545, United States
  • Palatin Clinical Site 184
    West Des Moines, Iowa 50266, United States
  • Palatin Clinical Site 155
    Overland Park, Kansas 66202, United States
  • Palatin Clinical Site 104
    Wichita, Kansas 67211, United States
  • Palatin Clinical Site 191
    Louisville, Kentucky 40291, United States
  • Palatin Clinical Site 194
    Eunice, Louisiana 70535, United States
  • Palatin Clinical Site 186
    New Orleans, Louisiana 70119, United States
  • Palatin Clinical Site 183
    Bangor, Maine 04401, United States
  • Palatin Clinical Site 159
    Annapolis, Maryland 21401, United States
  • Palatin Clinical Site 119
    Boston, Massachusetts 02131, United States
  • Palatin Clinical Site 126
    Watertown, Massachusetts 02472, United States
  • Palatin Clinical Site 163
    Bingham Farms, Michigan 48025, United States
  • Palatin Clinical Site 181
    Rochester, Michigan 48307, United States
  • Palatin Clinical Site 182
    Olive Branch, Mississippi 38654, United States
  • Palatin Clinical Site 170
    Saint Louis, Missouri 63141, United States
  • Palatin Clinical Site 180
    Billings, Montana 59102, United States
  • Palatin Clinical Site 192
    Norfolk, Nebraska 68701, United States
  • Palatin Clinical Site 168
    Omaha, Nebraska 68114, United States
  • Palatin Clinical Site 111
    Las Vegas, Nevada 89106, United States
  • Palatin Clinical Site 125
    Las Vegas, Nevada 89119, United States
  • Palatin Clinical Site 109
    Las Vegas, Nevada 89128, United States
  • Palatin Clinical Site 195
    Las Vegas, Nevada 89128, United States
  • Palatin Clinical Site 120
    Moorestown, New Jersey 08057, United States
  • Palatin Clinical Site 123
    Plainsboro, New Jersey 08536, United States
  • Palatin Clinical Site 124
    Albuquerque, New Mexico 87106, United States
  • Palatin Clinical Site 189
    Johnson City, New York 13790, United States
  • Palatin Clinical Site 107
    New York, New York 10016, United States
  • Palatin Clinical Site 158
    Port Jefferson, New York 11777, United States
  • Palatin Clinical Site 127
    Poughkeepsie, New York 12601, United States
  • Palatin Clinical Site 190
    Rochester, New York 14609, United States
  • Palatin Clinical Site 137
    Charlotte, North Carolina 28209, United States
  • Palatin Clinical Site 135
    Winston-Salem, North Carolina 27103, United States
  • Palatin Clinical Site 156
    Winston-Salem, North Carolina 27103, United States
  • Palatin Clinical Site 139
    Fargo, North Dakota 58103, United States
  • Palatin Clinical Site 140
    Akron, Ohio 44311, United States
  • Palatin Clinical Site 122
    Beachwood, Ohio 44122, United States
  • Palatin Clinical Site 151
    Cincinnati, Ohio 45227, United States
  • Palatin Clinical Site 112
    Columbus, Ohio 43213, United States
  • Palatin Clinical Site 115
    Englewood, Ohio 45322, United States
  • Palatin Clinical Site 132
    Medford, Oregon 97504, United States
  • Palatin Clinical Site 146
    Portland, Oregon 97210, United States
  • Palatin Clinical Site 169
    Jenkintown, Pennsylvania 19046, United States
  • Palatin Clinical Site 172
    Media, Pennsylvania 19063, United States
  • Palatin Clinical Site 117
    Warwick, Rhode Island 02886, United States
  • Palatin Clinical Site 162
    Anderson, South Carolina 29621, United States
  • Palatin Clinical Site 143
    Bluffton, South Carolina 29910, United States
  • Palatin Clinical Site 114
    Mount Pleasant, South Carolina 29464, United States
  • Palatin Clinical Site 145
    Mount Pleasant, South Carolina 29464, United States
  • Palatin Clinical Site 161
    Memphis, Tennessee 38119, United States
  • Palatin Clinical Site 129
    Nashville, Tennessee 37203, United States
  • Palatin Clinical Site 174
    Bryan, Texas 77802, United States
  • Palatin Clinical Site 113
    Dallas, Texas 75231, United States
  • Palatin Clinical Site 118
    San Antonio, Texas 78229, United States
  • Palatin Clinical Site 176
    Sugar Land, Texas 77479, United States
  • Palatin Clinical Site 100
    Murray, Utah 84123, United States
  • Palatin Clinical Site 103
    Charlottesville, Virginia 22903, United States
  • Palatin Clinical Site 138
    Virginia Beach, Virginia 23456, United States
  • Palatin Clinical Site 133
    Spokane, Washington 99207, United States
  • Palatin Clinical Site 150
    Tacoma, Washington 98405, United States
  • Palatin Clinical Site 193
    Middleton, Wisconsin 53562, United States
  • Palatin Clinical Site 304
    Halifax, Nova Scotia B35 1M7, Canada
  • Palatin Clinical Site 303
    Kentville, Nova Scotia B4N 4K9, Canada
  • Palatin Clinical Site 301
    Toronto, Ontario M9W 4L6, Canada
  • Palatin Clinical Site 302
    Saint Romuald, Quebec G6W 5M6, Canada
09

References and documents

Publications

  • Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597. PubMed 10782451 ↗
  • Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022 Feb;31(2):171-182. doi: 10.1089/jwh.2021.0191. PubMed 35147466 ↗
  • Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, Williams LA, Sadiq A, Krop J. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. J Womens Health (Larchmt). 2021 Apr;30(4):587-595. doi: 10.1089/jwh.2020.8460. Epub 2021 Feb 3. PubMed 33538638 ↗
  • Revicki DA, Althof SE, Derogatis LR, Kingsberg SA, Wilson H, Sadiq A, Krop J, Jordan R, Lucas J. Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. J Patient Rep Outcomes. 2020 Oct 8;4(1):82. doi: 10.1186/s41687-020-00241-6. PubMed 33033885 ↗
  • Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PubMed 31599847 ↗
  • Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PubMed 31599840 ↗
  • Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. Epub 2017 Feb 9. PubMed 28189361 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 4 years 5 months after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2014
First posted
Jan 7, 2015
Start
Dec 2014
Primary completionActual
Jul 2016
CompletionActual
Jun 30, 2017
Results delay requested
Sep 27, 2018
Results first posted
Dec 23, 2020
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02333071
Lead sponsor
Palatin Technologies, Inc
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Dec 2014
Primary completion
Jul 2016
Completion
Jun 30, 2017
Results posted
Dec 23, 2020
Last update
Apr 9, 2021

Study contacts

Robert Jordan
study director · Palatin Technologies, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion